Company profile
Ticker
CLB
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Core Laboratories Luxembourg S.A.
SEC CIK
Corporate docs
Subsidiaries
Core Laboratories Australia PTY LTD • Core Laboratories International B.V. • Core Laboratories LP • Core Laboratories Malaysia SDN BHD • Core Laboratories Sales B.V. • Core Laboratories (U.K.) Limited • Owen Oil Tools LP • Saybolt Nederland B.V. ...
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
25 Apr 24
8-K
First Quarter Revenue of $129.6 Million, Up Modestly Sequentially and Year-over-year
24 Apr 24
ARS
2023 FY
Annual report to shareholders
27 Mar 24
8-K
Departure of Directors or Certain Officers
25 Mar 24
DEFA14A
Additional proxy soliciting materials
18 Mar 24
DEF 14A
Definitive proxy
18 Mar 24
10-K
2023 FY
Annual report
14 Feb 24
8-K/A
Results of Operations and Financial Condition
14 Feb 24
8-K
Fourth Quarter Revenue of $128.2 Million, Up 2% Sequentially
31 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 16.62 mm | 16.62 mm | 16.62 mm | |||
Cash burn (monthly) | 3.20 mm | (no burn) | (no burn) | |||
Cash used (since last report) | 22.16 mm | n/a | n/a | |||
Cash remaining | -5.54 mm | n/a | n/a | |||
Runway (months of cash) | -1.7 | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 177 |
Opened positions | 24 |
Closed positions | 11 |
Increased positions | 54 |
Reduced positions | 63 |
13F shares | Current |
---|---|
Total value | 1.15 tn |
Total shares | 48.08 mm |
Total puts | 10.60 k |
Total calls | 39.60 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Ariel Investments | 9.06 mm | $217.62 bn |
BLK Blackrock | 7.76 mm | $186.27 bn |
Vanguard | 5.36 mm | $128.70 bn |
Earnest Partners | 3.78 mm | $90.80 bn |
Boston Trust Walden | 2.28 mm | $54.69 bn |
STT State Street | 2.08 mm | $49.90 bn |
Fred Alger Management | 1.33 mm | $31.87 bn |
Congress Asset Management | 1.12 mm | $27.01 bn |
AMP Ameriprise Financial | 962.09 k | $23.10 bn |
Geode Capital Management | 941.91 k | $22.62 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Apr 24 | Sow Hang Teo | Performance Shares Common Stock | Grant | Acquire A | No | No | 0 | 6,662 | 0.00 | 6,662 |
1 Apr 24 | Anastasio Curt | Common Stock | Option exercise | Acquire M | No | No | 0 | 6,419 | 0.00 | 6,419 |
1 Apr 24 | Anastasio Curt | Restricted Shares Common Stock | Option exercise | Dispose M | No | No | 0 | 6,419 | 0.00 | 0 |
1 Apr 24 | Anastasio Curt | Restricted Shares Common Stock | Grant | Acquire A | No | No | 0 | 9,317 | 0.00 | 9,317 |
1 Apr 24 | Carnes Martha Z. | Common Stock | Option exercise | Acquire M | No | No | 0 | 6,419 | 0.00 | 37,011 |
1 Apr 24 | Carnes Martha Z. | Restricted Shares Common Stock | Option exercise | Dispose M | No | No | 0 | 6,419 | 0.00 | 0 |
1 Apr 24 | Carnes Martha Z. | Restricted Shares Common Stock | Grant | Acquire A | No | No | 0 | 9,317 | 0.00 | 9,317 |
1 Apr 24 | Harvey Robert Klingensmith | Common Stock | Option exercise | Acquire M | No | No | 0 | 6,419 | 0.00 | 32,645 |
1 Apr 24 | Harvey Robert Klingensmith | Restricted Shares Common Stock | Option exercise | Dispose M | No | No | 0 | 6,419 | 0.00 | 0 |
1 Apr 24 | Harvey Robert Klingensmith | Restricted Shares Common Stock | Grant | Acquire A | No | No | 0 | 9,317 | 0.00 | 9,317 |
News
Core Laboratories Q1 2024 Adj EPS $0.19 Beats $0.16 Estimate, Sales $129.637M Beat $124.442M Estimate
24 Apr 24
B of A Securities Maintains Underperform on Core Laboratories, Lowers Price Target to $16
15 Apr 24
Top Cannabis Appointments You Should Know About: Aurora's New CFO And Other Changes
20 Feb 24